• LTGO share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of LTGO shares has increased $1.21 since the market last closed. This is a 8.18% rise.

  • Last closed at $16.00.

Key terms

About LTGO

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.06B

    A market capitalization between $300 million and $2 billion places LTGO in the small capitalization category.

Key terms

Smart score

Latest LTGO news

Sep 08, 2026 6:01am ET The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’ by TipRanks Sep 02, 2026 5:00am ET Analysts Offer Insights on NA Companies: Latigo Biotherapeutics, Inc. (LTGO), Golar LNG (GLNG) and Mobility Global Inc (MBGL) by TipRanks Sep 01, 2026 6:25am ET Latigo Biotherapeutics initiated with a Buy at Jefferies by TipRanks Sep 01, 2026 6:10am ET Latigo Biotherapeutics initiated with an Outperform at Leerink by TipRanks Sep 01, 2026 5:25am ET Latigo Biotherapeutics initiated with a Buy at Guggenheim by TipRanks Sep 01, 2026 4:30am ET Latigo Biotherapeutics initiated with a Buy at Goldman Sachs by TipRanks Sep 01, 2026 2:25am ET Salveen Richter Initiates Buy on Latigo for Differentiated Non‑Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential by TipRanks Aug 10, 2026 6:20pm ET Latigo Biotherapeutics Completes IPO and Updates Governance by TipRanks Aug 10, 2026 11:20am ET Opening Day: Biotech names lead week’s IPO activity by TipRanks Aug 07, 2026 11:45am ET Latigo Biotherapeutics opens at $21, IPO priced at $18 per share by TipRanks Aug 07, 2026 10:11am ET Latigo Biotherapeutics indicated to open at $20, IPO priced at $18 by TipRanks Aug 06, 2026 11:00pm ET Latigo Biotherapeutics 19.2M share IPO priced at $18.00 by TipRanks
Sep 03, 2026 4:05pm ET Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights by GlobeNewswire Aug 06, 2026 8:03pm ET Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering by GlobeNewswire Aug 06, 2026 8:03pm ET Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering by GlobeNewswire

LTGO Financials

1-year income & revenue

  • LTGO total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • LTGO net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • LTGO earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

LTGO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

LTGO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    LTGO's competitors are included in the Health Technology sector and Pharmaceuticals: Major group

  • Market cap: $1.06B

    A market capitalization between $300 million and $2 billion places LTGO in the small capitalization category.

Key terms

Latest investing news